Stryker Corporation $SYK Shares Sold by Handelsbanken Fonder AB

Key Points

• Handelsbanken Fonder AB reduced its Stryker stake by 1.1% in the second quarter, selling 3,128 shares and retaining 287,125 shares valued at approximately $90.4 million. Institutional investors and hedge funds collectively own 77.09% of the company.
• Stryker reported quarterly EPS of $3.69, exceeding the $3.49 analyst consensus, while revenue rose 9.4% year over year to $6.59 billion. The company provided fiscal 2026 EPS guidance of $14.95–$15.10.
• The stock was recently priced at $345.05, while analysts maintained a consensus “Moderate Buy” rating and an average price target of $386.28. Stryker also declared a quarterly dividend of $0.88 per share, representing a 1.0% yield.

Handelsbanken Fonder AB decreased its position in Stryker Corporation (NYSE:SYK - Free Report) by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,125 shares of the medical technology company's stock after selling 3,128 shares during the quarter. Handelsbanken Fonder AB owned 0.07% of Stryker worth $90,398,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock valued at $11,917,396,000 after buying an additional 133,892 shares during the period. State Street Corp boosted its holdings in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company's stock valued at $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC boosted its holdings in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company's stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the period. Wellington Management Group LLP grew its position in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Norges Bank acquired a new position in Stryker in the 4th quarter valued at about $1,822,272,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 1.8%

SYK stock opened at $345.05 on Tuesday. The company's 50 day moving average price is $321.03 and its 200 day moving average price is $333.81. The firm has a market capitalization of $132.35 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 2.16 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm earned $3.13 earnings per share. The firm's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. 4.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. UBS Group started coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price target on the stock. Truist Financial lifted their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a report on Friday, July 31st. Raymond James Financial set a $370.00 target price on shares of Stryker in a research note on Friday, July 31st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Finally, Wells Fargo & Company decreased their price target on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source